Literature DB >> 11392584

Effect of budesonide and nedocromil sodium on IL-6 and IL-8 release from human nasal mucosa and polyp epithelial cells.

A Xaubet1, J Mullol, J Roca-Ferrer, L Pujols, M Fuentes, M Pérez, J M Fabra, C Picado.   

Abstract

We investigated the effect of budesonide and nedocromil sodium on the secretion of IL-6 and IL-8 by cultured epithelial cells from healthy nasal mucosa and nasal polyps. Human epithelial cell conditioned media was generated with fetal calf serum (FCS) in the presence or absence of budesonide and/or nedocromil sodium. Budesonide inhibited FCS-induced IL-6 and IL-8 release in a dose-dependent manner. The IC25 (25% inhibitory concentration) of budesonide on IL-6 release was higher in nasal polyp than in nasal mucosa epithelial cells (34 nM vs. 200 pM). The IC25 of budesonide on IL-8 release was higher in nasal mucosa than in nasal polyps (145 pM vs. 4 pM). Nedocromil sodium caused a dose-related inhibitory effect on IL-8 release from nasal mucosa (IC25, 207 nM), while it only had a significant effect in nasal polyps at 10(-5) M. Nedocromil sodium had no effect on IL-6 release. The inhibitory effect of budesonide was higher than that of nedocromil sodium on both nasal polyps and nasal mucosa. Budesonide and nedocromil sodium may exert their anti-inflammatory action in the respiratory mucosa by modulating the secretion of IL-6 and IL-8. The different effect of budesonide and nedocromil sodium on IL-6 and IL-8 release may be explained by differences in the mechanisms which regulate the upregulation of these cytokines in inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11392584     DOI: 10.1053/rmed.2001.1061

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

Review 1.  Role of medical therapy in the management of nasal polyps.

Authors:  Isam Alobid; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

Review 2.  The role of local steroid injection for nasal polyposis.

Authors:  Marcelo B Antunes; Samuel S Becker
Journal:  Curr Allergy Asthma Rep       Date:  2010-05       Impact factor: 4.806

Review 3.  Contemporary Use of Corticosteroids in Rhinology.

Authors:  Alexander Karatzanis; Alkiviadis Chatzidakis; Athanasia Milioni; Stephan Vlaminck; Hideyuki Kawauchi; Stylianos Velegrakis; Emmanuel Prokopakis
Journal:  Curr Allergy Asthma Rep       Date:  2017-02       Impact factor: 4.806

4.  Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells.

Authors:  Joaquim Mullol; Francisco de Borja Callejas; Maria Asunción Martínez-Antón; Eva Méndez-Arancibia; Isam Alobid; Laura Pujols; Antonio Valero; Cesar Picado; Jordi Roca-Ferrer
Journal:  Respir Res       Date:  2011-02-27

5.  Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers.

Authors:  Jordi Roca-Ferrer; Laura Pujols; Maria Pérez-González; Isam Alobid; Borja Callejas; Sònia Vicens-Artés; Mireya Fuentes; Antonio Valero; César Picado; Dennis Castor; DucTung Nguyen; Joaquim Mullol
Journal:  Allergy Asthma Clin Immunol       Date:  2018-12-18       Impact factor: 3.406

6.  Chronic rhinosinusitis and emerging treatment options.

Authors:  Patorn Piromchai; Pornthep Kasemsiri; Supawan Laohasiriwong; Sanguansak Thanaviratananich
Journal:  Int J Gen Med       Date:  2013-06-07

Review 7.  Brazilian Academy of Rhinology position paper on topical intranasal therapy.

Authors:  João Ferreira de Mello; Olavo de Godoy Mion; Nilvano Alves de Andrade; Wilma Terezinha Anselmo-Lima; Aldo Eden Cassol Stamm; Washingthon Luiz de Cerqueira Almeida; Pedro Oliveira Cavalcante Filho; Jair de Carvalho e Castro; Francini Grecco de Melo Padua; Fabrizio Ricci Romano; Rodrigo de Paulo Santos; Renato Roitmann; Richard Louis Voegels; Roberto Campos Meirelles; Leonardo Conrado Barbosa Sá; Moacyr Tabasnik Moacyr; Marco Cesar Jorge dos Santos; Roberto Eustáquio Santos Guimarães
Journal:  Braz J Otorhinolaryngol       Date:  2013 May-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.